Comparative Pharmacology
Head-to-head clinical analysis: LIDODERM versus SEPTOCAINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LIDODERM versus SEPTOCAINE.
LIDODERM vs SEPTOCAINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Lidocaine is an amide-type local anesthetic that blocks voltage-gated sodium channels (Nav1.7) in nerve cell membranes, inhibiting depolarization and conduction of nerve impulses, thereby producing both local anesthesia and systemic analgesia.
Articaine is a local anesthetic of the amide type that stabilizes the neuronal membrane by inhibiting sodium ion influx, thereby blocking nerve impulse conduction.
Apply 1 to 3 patches (5% lidocaine) to intact skin over most painful area for up to 12 hours within a 24-hour period; maximum 3 patches at once.
SEPTOCAINE (articaine HCl 4% with epinephrine 1:100,000 or 1:200,000) dental infiltration or nerve block: 0.5–1.7 mL (20–68 mg articaine) per injection site; maximum adult dose: 7 mg/kg (up to 500 mg total).
None Documented
None Documented
Terminal elimination half-life is 3–5 hours after topical application; after intravenous administration, half-life is 1.5–2 hours. Clinical context: Systemic accumulation possible with prolonged use on inflamed skin.
Terminal elimination half-life in adults is 2-4 hours. In neonates, it may be prolonged to 8-12 hours due to immature hepatic function.
Renal excretion of metabolites (primarily 4-hydroxy-2,6-xylidine glucuronide) accounts for >85% of elimination; <3% excreted unchanged; biliary/fecal elimination minimal (<10%).
Primarily hepatic metabolism; less than 10% excreted unchanged in urine. Biliary/fecal elimination is negligible.
Category C
Category C
Local Anesthetic
Local Anesthetic